ストックスクリーナーアプリを入手
58.67
0.63%
0.37
アフターアワーズ：
58.67
前日終値:
$58.30
開ける：
$57.46
24時間の取引高:
193.44K
Relative Volume:
0.71
時価総額：
$392.07M
収益：
-
当期純損益:
$-19.44M
株価収益率:
-17.06
EPS:
-3.4389
ネットキャッシュフロー:
$-10.83M
1週間 パフォーマンス:
+1.86%
1か月 パフォーマンス:
+7.26%
6か月 パフォーマンス:
-7.30%
1年 パフォーマンス:
+50.05%
1日の値動き範囲:
$54.24
$60.59
1週間の範囲:
$54.24
$64.86
52週間の値動き範囲:
$26.05
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
名前
Monopar Therapeutics Inc
セクター
電話
(847) 388-0349
住所
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
58.67 | 389.59M | 0 | -19.44M | -10.83M | -3.4389 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-14 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 開始されました | Leerink Partners | Outperform |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-09-09 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | Oppenheimer | Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-08-26 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-19 | 再開されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Piper Sandler | Overweight |
| 2024-10-11 | 開始されました | Rodman & Renshaw | Buy |
| 2021-01-28 | 開始されました | ROTH Capital | Buy |
すべてを表示
Monopar Therapeutics Inc (MNPR) 最新ニュース
Jones Trading Downgrades Monopar Therapeutics (MNPR) - MSN
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC - MarketBeat
(MNPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
Published on: 2026-03-07 04:32:52 - baoquankhu1.vn
Monopar Therapeutics (MNPR) officer Susan Rodriguez submits initial Form 3 - Stock Titan
Monopar Therapeutics (MNPR) CCSO granted 48,728 stock options in new award - Stock Titan
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez - The Globe and Mail
MNPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monopar names Susan Rodriguez as chief commercial officer - Investing.com India
Responsive Playbooks and the MNPR Inflection - Stock Traders Daily
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - Bitget
Monopar expands leadership team with appointment of seasoned biopharma executive Susan Rodriguez as chief commercial and strategy officer - marketscreener.com
New Monopar (NASDAQ: MNPR) strategy chief to steer ALXN1840 NDA - Stock Titan
Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026 - marketscreener.com
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
BTIG Reiterates Buy Rating for MNPR with $104 Target Price | MNP - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research - MarketBeat
Is Monopar Therapeutics Inc. stock ready for breakoutWeekly Trading Summary & Accurate Intraday Trade Tips - mfd.ru
Can Monopar Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Short Interest & Trade Opportunity Analysis Reports - mfd.ru
Retail Trends: Will Monopar Therapeutics Inc benefit from sector rotationPrice Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Understanding the Setup: (MNPR) and Scalable Risk - Stock Traders Daily
RA Capital reports 9.99% Monopar Therapeutics stake in Schedule 13G/A (MNPR) - Stock Titan
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Monopar Therapeutics (NASDAQ:MNPR) Head to Head Comparison - Defense World
Why Monopar Therapeutics Inc. (1IY0) stock attracts wealthy investors2025 Bull vs Bear & Stepwise Entry and Exit Trade Signals - mfd.ru
MNPR PE Ratio & Valuation, Is MNPR Overvalued - Intellectia AI
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Should I add Monopar Therapeutics Inc. stock to my portfolio2025 Retail Activity & AI Based Trade Execution Alerts - mfd.ru
Stocks showing improved relative strength: Monopar Therapeutics - MSN
The Technical Signals Behind (MNPR) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 21.1% - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at BTIG Research - Defense World
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease - TipRanks
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Bull Bear: Why is Monopar Therapeutics Inc stock going down2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Precision Trading with Monopar Therapeutics Inc. (MNPR) Risk Zones - Stock Traders Daily
Breakout Move: Will Monopar Therapeutics Inc outperform tech stocksStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Market Leaders: Will Monopar Therapeutics Inc outperform tech stocksMarket Rally & Growth Focused Entry Reports - baoquankhu1.vn
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
Monopar Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Monopar Therapeutics: Tiny Cancer-Drug Stock Caught Between Speculation And Survival - AD HOC NEWS
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December - MarketBeat
Fundamentals Check: Why is Monopar Therapeutics Inc stock going downJuly 2025 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Monopar Therapeutics Inc (MNPR) 財務データ
収益
当期純利益
現金流量
EPS
1.20%
0.06%
大文字化:
|
ボリューム (24 時間):